Contemporary concepts of uterine fibroids’ pathogenesis

封面

如何引用文章

全文:

详细

Uterine myoma is the most common benign tumor among women which affects mainly those of reproductive age. Moreover, the frequency of emergence of this pathology in population is growing while the age of patients is steadily decreasing. Despite the enormous prevalence of this disease, its pathogenesis has not been studied properly. This article is concerned with an analysis of publications devoted to the study of the mechanisms of growth and development of uterine fibroids, it provides some data on the role of various factors in its extension. The article concerns the most popular concepts of the pathogenesis of this disease according to which the illness may be caused by increased levels of sex hormones (estrogens and progestins), enhanced expression of their receptors, impaired apoptosis, the effect of growth factors (e. g. epidermal growth factor, heparin-binding epidermal growth factor, acid and basic fibroblast growth factors, vascular endothelial growth factor, insulin-like growth factor, platelet-derived growth factor, transforming growth factor-β, activin, myostatin), abnormal deposition extracellular matrix, genetic (chromosomal aberration and various MED12 gene defect) and epigenetic mechanisms (such as action microRNA), circulatory disorders and impairment of cell differentiation from a population of accessory stem cells. However, it is noted that the pathogenesis of this pathology requires further detailed study, as the understanding of the processes leading to its development could greatly contribute to the improvement of the tactics of treatment and possibly allow to elaborate some preventive measures to avert the development of fibroids.

作者简介

Anna Taits

St. Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation

编辑信件的主要联系方式.
Email: annataits1@rambler.ru

MD, PhD, Associate Professor, Department of Obstetrics and Gynecology

俄罗斯联邦, Saint Petersburg

Nikolai Ruhljada

St. Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation

Email: nickolasr@mail.ru

MD, PhD, Dr Med Sci, Professor, Head, Department of Obstetrics and Gynecology

俄罗斯联邦, Saint Petersburg

Valeriy Matukhin

St. Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation

Email: val-matukhin@mail.ru

Second-year Resident, Department of Obstetrics and Gynecology

俄罗斯联邦, Saint Petersburg

Aleksandra Somova

St. Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation

Email: alexadra.sayko@mail.ru

Student of the 5th Course

俄罗斯联邦, Saint Petersburg

Kristina Dudova

St. Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation

Email: kristinada16@gmail.com

Student of the 5th Course

俄罗斯联邦, Saint Petersburg

参考

  1. Биличенко М.В., Бушуева О.Ю., Кудрявцева О.К., и др. Исследование ассоциации полиморфизма 754с/g гена FGFII с развитием миомы матки // Курский научно-практический вестник «Человек и его здоровье». - 2013. - № 2. - С. 5-8. [Bilichenko MV, Bushueva OY, Kudryavtseva OK, et al. Association between genetic polymorphism 754С/G in FGFII gene and risk of hysteromyoma. Kurskiy nauchno-prakticheskiy vestnik “Chelovek i ego zdorov’e”. 2013;(2):5-8. (In Russ.)]
  2. Джемлиханова Л.Х., Смирнова М.Ю., Ниаури Д.А., Кветной И.М. Экспрессия рецепторов половых стероидных гормонов и факторов роста в миометрии при миоме матки и аденомиозе // Вестник Санкт-Петербургского университета. Серия Медицина. - 2009. - № 4. - С. 222-230. [Dzhemlikhanova LK, Smirnova MY, Niauri DA, Kvetnoy IM. Expression of receptors of sex steroid hormones and growth factors in miometrium in patients with uterine myoma and adenomyozis. Vestnik Sankt-Peterburgskogo universiteta. Seriia 11. Meditsina. 2009;(4):222-230. (In Russ.)]
  3. Министерство здравоохранения РФ. Миома матки: диагностика, лечение и реабилитация: Клинические рекомендации. - М., 2015. [Ministerstvo zdravookhraneniya RF. Mioma matki: diagnostika, lechenie i reabilitatsiya: Klinicheskie rekomendatsii. Moscow; 2015. (In Russ.)]
  4. Муратова Н.Д., Абдувалиев А.А. Влияние трансформирующего фактора роста β2 на пролиферацию клеток лейомиомы матки // Казанский медицинский журнал. - 2015. - № 6. - С. 968-970. [Muratova ND, Abduvaliev AA. Effect of transforming growth factor-β2 on uterine leiomyoma cells proliferation. Kazan Med Zh. 2015;(6):968-970. (In Russ.)]
  5. Радзинский В.Е., Архирова М.П. Миома матки: проблемы и перспективы начала века // Медицинский совет. - 2014. - № 9. - С. 30-33. [Radzinskiy VE, Arkhirova MP. Uterine fibroids: problems and prospects at the turn of the century. Meditsinskiy sovet. 2014;(9):30-33. (In Russ.)]
  6. Радзинский В.Е., Тотчиев Г.Ф. Миома матки: курс на органосохранение. - М.: StatusPraesens, 2014. [Radzinskiy VE, Totchiev GF. Mioma matki: kurs na organosokhranenie. Moscow: StatusPraesens; 2014. (In Russ.)]
  7. Тапильская Н.И., Духанин А.С., Глушаков Р.И. Медикаментозное лечение симптомной миомы матки // Проблемы репродукции. - 2018. - № 4. - С. 81-88. [Tapil’skaya NI, Dukhanin AS, Glushakov RI. Influence of drug treatment of symptomatic uterine leiomyoma on the quality of life of women. Modern reproductive technologies. 2018;(4):81-88. (In Russ.)]
  8. Тихомиров А.Л. Агонисты гонадотропных рилизинг-гормонов в лечении миомы матки // Русский медицинский журнал. Мать и дитя. - 2010. - Т. 18. - № 4. - С. 188-191. [Tikhomirov AL. Agonisty gonadotropnykh rilizing-gormonov v lechenii miomy matki. Russkiy medicinskiy zhurnal. Mat’ i ditya. 2010;18(4):188-191. (In Russ.)]
  9. Тихомиров А.Л. Патогенетическое обоснование ранней диагностики, лечения и профилактики миомы матки: Автореф. дис. … д-ра мед. наук. - М., 1998. [Tikhomirov AL. Patogeneticheskoe obosnovanie ranney diagnostiki, lecheniya i profilaktiki miomy matki. [dissertation] Moscow; 1998. (In Russ.)]
  10. Сафарова С.М. Морфологическая характеристика миомы матки среди женщин репродуктивного возраста // Журнал акушерства и женских болезней. - 2017. - Т. 66. - № 1. - С. 27-31. [Safarova SM. Morphological characteristics of uterine fibroids among women of reproductive age. Journal of obstetrics and women’s diseases. 2017;66(1):27-31. (In Russ.)]. https://doi.org/10.17816/JOWD66127-31.
  11. Сидорова И.С., Унанян А.Л., Агеев М.Б., и др. Современное состояние вопроса о патогенезе, клинике. диагностике и лечении миомы матки у женщин репродуктивного возраста // Акушерство, гинекология и репродукция. - 2012. - Т. 6. - № 4. - С. 22-28. [Sidorova IS, Unanyan AL, Ageev MB, et al. Current status of the pathogenesis, clinical features, diagnosis, and treatment. Akusherstvo, ginekologiya i reproduktsiya. 2012;6(4):22-28. (In Russ.)]
  12. Согоян Н.С., Адамян Л.В. Генетические механизмы развития миомы матки // Проблемы репродукции. - 2016. - № 1. - С. 28-34. [Sogoyan NS, Adamyan LV. Genetic mechanisms of uterine leiomyoma. Modern reproductive technologies. 2016;(1):28-34. (In Russ.)]
  13. Bao H, Sin TK, Zhang G. Activin A induces leiomyoma cell proliferation, extracellular matrix (ECM) accumulation and myofibroblastic transformation of myometrial cells via p38 MAPK. Biochem Biophys Res Commun. 2018;504(2): 447-53. https://doi.org/10.1016/j.bbrc.2018.08.171.
  14. Bao H, Sin TK, Zhang G. Activin A induces leiomyoma cell proliferation, extracellular matrix (ECM) accumulation and myofibroblastic transformation of myometrial cells via p38 MAPK. Biochem Biophys Res Commun. 2018;504(2):447-453. https://doi.org/10.1016/j.bbrc.2018.08.171.
  15. Mas A, Cervello I, Gil-Sanchis C, et al. Identification and characterization of the human leiomyoma side population as putative tumor-initiating cells. Fertil Steril. 2012;98(3):741-751.e746. https://doi.org/10.1016/j.fertnstert.2012.04.044.
  16. Ciarmela P, Islam MS, Reis FM, et al. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum Reprod Update. 2011;17(6):772-790. https://doi.org/10.1093/humupd/dmr031.
  17. Doherty LF, Taylor HS. Leiomyoma-derived transforming growth factor-beta impairs bone morphogenetic protein-2-mediated endometrial receptivity. Fertil Steril. 2015;103(3):845-852. https://doi.org/10.1016/j.fertnstert.2014.12.099.
  18. Fitzgerald JB, Chennathukuzhi V, Koohestani F, et al. Role of microRNA-21 and programmed cell death 4 in the pathogenesis of human uterine leiomyomas. Fertil Steril. 2012;98(3):726-734 e722. https://doi.org/10.1016/j.fertnstert.2012.05.040.
  19. Islam MS, Ciavattini A, Petraglia F, et al. Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics. Hum Reprod Update. 2018;24(1):59-85. https://doi.org/10.1093/humupd/dmx032.
  20. Meduri G, Bausero P, Perrot-Applanat M. Expression of vascular endothelial growth factor receptors in the human endometrium: modulation during the menstrual cycle. Biol Reprod. 2000;62(2):439-447. https://doi.org/10.1095/biolreprod62.2.439.
  21. Orciani M, Caffarini M, Biagini A, et al. Chronic inflammation may enhance leiomyoma development by the involvement of progenitor cells. Stem Cells Int. 2018;2018:1716246. https://doi.org/10.1155/2018/1716246.
  22. Protic O, Toti P, Islam MS, et al. Possible involvement of inflammatory/reparative processes in the development of uterine fibroids. Cell Tissue Res. 2016;364(2):415-27. https://doi.org/10.1007/s00441-015-2324-3.
  23. Ren Y, Yin H, Tian R, et al. Different effects of epidermal growth factor on smooth muscle cells derived from human myometrium and from leiomyoma. Fertil Steril. 2011;96(4):1015-1020. https://doi.org/10.1016/j.fertnstert.2011.07.004.
  24. Suo G, Jiang Y, Cowan B, Wang JY. Platelet-derived growth factor C is upregulated in human uterine fibroids and regulates uterine smooth muscle cell growth. Biol Reprod. 2009;81(4):749-758. https://doi.org/10.1095/biolreprod.109.076869.
  25. Takahashi N, Yoshino O, Hiraike O, et al. The assessment of myometrium perfusion in patients with uterine fibroid by arterial spin labeling MRI. Springerplus. 2016;5(1):1907. https://doi.org/10.1186/s40064-016-3596-0.
  26. Vlahos NF, Theodoridis TD, Partsinevelos GA. Myomas and adenomyosis: impact on reproductive outcome. Biomed Res Int. 2017;2017:5926470. https://doi.org/10.1155/2017/5926470.
  27. Wang J, Ohara N, Takekida S, et al. Comparative effects of heparin-binding epidermal growth factor-like growth factor on the growth of cultured human uterine leiomyoma cells and myometrial cells. Hum Reprod. 2005;20(6):1456-1465. https://doi.org/10.1093/humrep/deh842.
  28. Wolanska M, Bankowski E. Transforming growth factor beta and platelet-derived growth factor in human myometrium and in uterine leiomyomas at various stages of tumour growth. Eur J Obstet Gynecol Reprod Biol. 2007;130(2):238-244. https://doi.org/10.1016/j.ejogrb.2006.01.034.
  29. Wolanska M, Malkowski A, Romanowicz L, Bankowski E. Does vascular endothelial growth factor participate in uterine myoma growth stimulation? Eur J Obstet Gynecol Reprod Biol. 2012;164(1):93-97. https://doi.org/10.1016/j.ejogrb.2012.05.021.
  30. Wong JY, Gold EB, Johnson WO, Lee JS. Circulating Sex Hormones and Risk of Uterine Fibroids: Study of Women’s Health Across the Nation (SWAN). J Clin Endocrinol Metab. 2016;101(1):123-130. https://doi.org/10.1210/jc.2015-2935.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Taits A.N., Ruhljada N.N., Matukhin V.I., Somova A.D., Dudova K.A., 2019

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
 


##common.cookie##